AstraZeneca's Farxiga nabs first CV approval from the FDA. Will a bigger one follow
The Holy Grail for AstraZeneca’s SGLT2 med Farxiga is an approval to treat heart failure in patients with or without diabetes—and it’s well on its way to that goal. But while it waits for that game-changing win, Farxiga will take a heart-helping approval for diabetes patients. The FDA on Monday approved Farxiga to reduce the risk of heart failure hospitalizations in patients with Type 2 diabetes, the drug’s first cardiovascular approval. Regulators based the decision on outcomes trial data showing that Farxiga could cut the rate of hospitalizations by 36% among heart failure patients with a reduced ejection fraction and by 24% among those without one. Farxiga already has the data on its label in Europe, where it's known as Forxiga
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
